Cannabinoid treatment for the symptoms of autism spectrum disorder
INTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 3% of school-age children. The core symptoms are deficits in social communication and restricted and repetitive patterns of behavior. Associated problems in cognition, language, behavior, sleep and mood are prevalent. Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used to manage associated irritability, but their effectiveness is limited and adverse events are common.
AREAS COVERED: This mini-review summarizes existing scientific literature and ongoing clinical trials concerning cannabinoid treatment for ASD. Uncontrolled case series have documented improvements in both core ASD symptoms and related behavioral challenges in children treated with cannabis extracts rich in cannabidiol (CBD). Placebo-controlled studies involving CBD-rich cannabis extracts and/or pure CBD in children with ASD have demonstrated mixed efficacy results. A similar outcome was observed in a placebo-controlled study of pure CBD addressing social avoidance in Fragile X syndrome. Importantly, these studies have shown relatively high safety and tolerability.
EXPERT OPINION: While current clinical data suggest the potential of CBD and CBD-rich cannabis extract in managing core and behavioral deficits in ASD, it is prudent to await the results of ongoing placebo-controlled trials before considering CBD treatment for ASD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 29(2024), 1 vom: 16. März, Seite 65-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aran, Adi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19GBJ60SN5 |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2024.2306290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367171430 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367171430 | ||
| 003 | DE-627 | ||
| 005 | 20240320233942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2024.2306290 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM367171430 | ||
| 035 | |a (NLM)38226593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aran, Adi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoid treatment for the symptoms of autism spectrum disorder |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 3% of school-age children. The core symptoms are deficits in social communication and restricted and repetitive patterns of behavior. Associated problems in cognition, language, behavior, sleep and mood are prevalent. Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used to manage associated irritability, but their effectiveness is limited and adverse events are common | ||
| 520 | |a AREAS COVERED: This mini-review summarizes existing scientific literature and ongoing clinical trials concerning cannabinoid treatment for ASD. Uncontrolled case series have documented improvements in both core ASD symptoms and related behavioral challenges in children treated with cannabis extracts rich in cannabidiol (CBD). Placebo-controlled studies involving CBD-rich cannabis extracts and/or pure CBD in children with ASD have demonstrated mixed efficacy results. A similar outcome was observed in a placebo-controlled study of pure CBD addressing social avoidance in Fragile X syndrome. Importantly, these studies have shown relatively high safety and tolerability | ||
| 520 | |a EXPERT OPINION: While current clinical data suggest the potential of CBD and CBD-rich cannabis extract in managing core and behavioral deficits in ASD, it is prudent to await the results of ongoing placebo-controlled trials before considering CBD treatment for ASD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autism | |
| 650 | 4 | |a CBD | |
| 650 | 4 | |a THC | |
| 650 | 4 | |a cannabinoids | |
| 650 | 4 | |a cannabis | |
| 650 | 4 | |a endocannabinoid system | |
| 650 | 4 | |a pharmacological treatments | |
| 650 | 4 | |a review | |
| 650 | 7 | |a Aripiprazole |2 NLM | |
| 650 | 7 | |a 82VFR53I78 |2 NLM | |
| 650 | 7 | |a Cannabidiol |2 NLM | |
| 650 | 7 | |a 19GBJ60SN5 |2 NLM | |
| 650 | 7 | |a Cannabinoids |2 NLM | |
| 700 | 1 | |a Cayam Rand, Dalit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 29(2024), 1 vom: 16. März, Seite 65-79 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:16 |g month:03 |g pages:65-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2024.2306290 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 16 |c 03 |h 65-79 | ||